FMR LLC raised its holdings in BioNTech SE (NASDAQ:BNTX - Free Report) by 22.2% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 7,701,476 shares of the company's stock after acquiring an additional 1,401,547 shares during the quarter. FMR LLC owned approximately 3.21% of BioNTech worth $877,583,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also bought and sold shares of BNTX. SG Americas Securities LLC grew its holdings in shares of BioNTech by 412.3% in the fourth quarter. SG Americas Securities LLC now owns 41,470 shares of the company's stock worth $4,726,000 after purchasing an additional 33,375 shares during the last quarter. Mirabaud & Cie SA bought a new position in BioNTech in the 4th quarter worth about $684,000. Bank of New York Mellon Corp grew its stake in BioNTech by 4.3% in the 4th quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company's stock worth $419,000 after acquiring an additional 150 shares in the last quarter. Vestcor Inc purchased a new position in shares of BioNTech during the third quarter worth approximately $784,000. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in shares of BioNTech during the fourth quarter valued at approximately $1,118,000. Hedge funds and other institutional investors own 15.52% of the company's stock.
BioNTech Stock Performance
BNTX traded up $3.40 during midday trading on Friday, hitting $96.52. 1,149,784 shares of the company were exchanged, compared to its average volume of 855,277. The company's 50 day simple moving average is $104.64 and its 200 day simple moving average is $111.63. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $23.16 billion, a price-to-earnings ratio of -45.96 and a beta of 1.07. BioNTech SE has a 1-year low of $76.53 and a 1-year high of $131.49.
BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings data on Monday, March 10th. The company reported $1.08 EPS for the quarter, topping analysts' consensus estimates of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.24 billion. During the same quarter last year, the company earned $1.90 EPS. The business's revenue was down 19.5% on a year-over-year basis. As a group, sell-side analysts predict that BioNTech SE will post -3.88 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of equities research analysts have weighed in on BNTX shares. Morgan Stanley decreased their target price on BioNTech from $145.00 to $139.00 and set an "overweight" rating for the company in a research report on Tuesday, March 11th. BMO Capital Markets upped their price objective on shares of BioNTech from $130.00 to $143.00 and gave the stock an "outperform" rating in a research note on Tuesday, March 11th. Canaccord Genuity Group reissued a "buy" rating and set a $171.44 target price on shares of BioNTech in a research report on Tuesday, March 11th. HC Wainwright lowered their price target on shares of BioNTech from $150.00 to $145.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Finally, Citigroup began coverage on BioNTech in a research note on Thursday, March 13th. They set a "buy" rating and a $145.00 price objective for the company. Three research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $143.44.
View Our Latest Research Report on BioNTech
About BioNTech
(
Free Report)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Further Reading
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
